Michael L. Levitz - 10 Aug 2023 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)

Role
EVP, CFO, Treasurer
Signature
/s/ Michael L. Levitz
Issuer symbol
ANIK
Transactions as of
10 Aug 2023
Net transactions value
-$21,051
Form type
4
Filing time
11 Aug 2023, 16:30:46 UTC
Previous filing
14 Mar 2023
Next filing
12 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANIK Common Stock Options Exercise $0 +3,859 +13% $0.000000 34,365 10 Aug 2023 Direct F1, F2
transaction ANIK Common Stock Tax liability $21,051 -1,133 -3.3% $18.58 33,232 10 Aug 2023 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANIK Restricted Stock Unit Options Exercise $0 -3,859 -100% $0.000000* 0 10 Aug 2023 Common Stock 3,859 $0.000000 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the third and final vesting installment of Restricted Stock Units (RSUs) granted on August 10, 2020.
F2 Includes 668 shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan on May 12, 2023.
F3 Reflects an aggregate of 1,133 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on August 10, 2023.
F4 Reflects the closing price of ANIK common stock on August 10, 2023, the trading day on which the vesting of RSUs gave rise to tax withholding obligations.
F5 Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning August 10, 2021.